Organs-on-Chips Substituting Animal Models in Scientific Research
Growth drivers such as the rising requirement for effective drug development and discovery, soaring demand for substitutes for animal models in research, surging government grants and research studies, and increasing drug repurposing approaches will fuel the organ-on-chip market at a massive CAGR of 40.1% during the forecast period (2018–2025). Government organizations provide grants to private companies to support research activities. The market generated revenue of $11.0 million in 2017, and it is expected to reach $163.1 million by 2025.
The robust search for alternatives to animal models in research activities has led to the large-scale adoption of organ-on-chip models globally. The approach of mimicking human diseases in animals has been facing disputes regarding their translatability and validity to humans. Organs-on-chips have the ability to address these complexities better than the current animal models that are being used by researchers in disease model studies. In addition, pharmaceutical companies are using organ-on-chip models for drug repurposing.
Access Summary - Organ-on-Chip Market Global Industry Analysis and Demand Forecast Report
Moreover, the surging requirement for personalized medication will widen the application base of organ-on-chip products. Additionally, biotech and pharma companies are improving the organ-on-chip technologies to be applied in cosmetics, agriculture, and chemical-based consumer products. For instance, the September 2016 collaboration between L'Oréal S.A. and the University of Central Florida (UCF) highlighted the challenge between the microfluidics technology and cellular engineering. The company expects that the organ-on-chip technology will benefit it by integrating different cell types derived from different organs, thereby increasing the lifespan of cells and offering a better prediction of drug efficacy and safety.
\
According to P&S Intelligence, North America was the largest consumer of organ-on-chip products in the past due to the huge investments by key pharma and biotech companies to explore the potential applications of such products and hefty grants offered by governments for organ-on-chip research. With the investment, key companies, including Organovo Holdings Inc., Emulate Inc., Ascendance Biotechnology Inc., and Nortis Inc., are working toward improving the costly, time-taking, and strenuous drug discovery procedures, by innovating their organ-on-chip technologies.
The Asia-Pacific (APAC) organ-on-chip market will witness the fastest growth during the forecast period. This can be ascribed to the soaring healthcare spending, surging adoption of advanced technologies, and increasing government funding and initiatives for R&D in the healthcare industry. At present, the APAC region is observing numerous research studies aimed at determining the potential of organs-on-chips as a novel platform for biological analysis. These R&D activities are backed by funding from government organizations, such as the National Key Scientific Instrument and Equipment Development Project of China and Chinese Academy of Sciences.
Thus, the surging need for effective drug development will boost the demand for organ-on-chip products in the coming years.